HB5609, titled the “Stop RFK’s Bad Science Act” or “Stop RFK’s BS Act,” would require the National Institutes of Health to reinstate certain grants or other awards that were terminated or suspended between January 20, 2025, and the date of enactment. The bill applies to “covered” NIH grants and awards unless the NIH Director finds financial mismanagement, research fraud, or malfeasance. If reinstated, the awards would be treated as obligated funds.
The bill also requires NIH to disburse approved payment requests for covered grants or awards as soon as possible, and no later than 30 calendar days after submission. In addition, any reinstated or newly disbursed covered grant or award would receive a one-year extension of its budget period, effectively giving recipients additional time to use the funds and complete the work supported by the award.
Impact
If enacted, the bill would directly constrain NIH discretion over the termination, suspension, and payment timing of grants and other awards, and would create a statutory mandate to restore funding for affected recipients absent specified misconduct findings. It would also alter the administration of NIH grant periods by extending the budget period for reinstated or disbursed awards by one year, potentially affecting project timelines, reporting, and spending authority for recipients and NIH program officials.
Sentiment
Based on the bill text and available context, the measure appears strongly supportive of NIH-funded researchers and recipients whose awards were cut or delayed, and it is framed as a corrective response to perceived politically driven or scientifically unsound funding decisions. The absence of recorded votes or committee debate means there is no documented bipartisan or committee sentiment in the provided materials, but the title and structure suggest a partisan and highly critical stance toward the current NIH leadership or administration.
Contention
The main point of contention is NIH authority to terminate or suspend grants and the circumstances under which those decisions should be reversed. Supporters would likely argue that the bill protects scientific research and prevents arbitrary funding disruptions, while opponents may argue it unduly limits agency discretion, could force reinstatement of awards even where program priorities have changed, and may create administrative burdens or reduce flexibility in managing federal research dollars. The bill’s exception for financial mismanagement, research fraud, or malfeasance indicates that the dispute centers on whether broader categories of terminations should be overridden by statute.